Amifostine and External Beam Radiation Therapy and/or High-Dose Rate Brachytherapy in the Treatment of Localized Prostate Carcinoma: Preliminary Results of a Phase II Trial

Seminars in Oncology

Volumn 30, Issue 6 SUPPL. 18, 2003, Pages 58-62

  Linares, Luis A ^a   Echols, Deborah ^a  

^a Memorial Medical Center New Orleans   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; FENTANYL CITRATE; HEART ENZYME; ROPIVACAINE;

ADULT; AGED; BEAM THERAPY; BRACHYTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; GASTROINTESTINAL TOXICITY; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; RADIATION PROTECTION; SKIN MANIFESTATION; UROGENITAL TRACT MALFORMATION;

EID: 1642476570     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.11.015     Document Type: Conference Paper

References (13)

1. Pilepich MW, Bagshaw MA, Asbell SO, et al: Radical prostatectomy or radiotherapy in carcinoma of prostate: The dilemma continues. Urology 30:18-21, 1987
2. Stokes SH: Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys 47:129-136, 2000 (suppl 1)
3. Pollack A, Zagars GK, Smith LG, et al: Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18:3904-3911, 2000 (suppl 23)
4. Hanks GE, Hanlon AL, Schultheiss TE, et al: Dose escalation with 3D conformal treatment: Five year outcome, treatment optimization and future directions. Int J Radiat Oncol Biol Phys 41:501-510, 1998 (suppl 3)
5. Brenner D, Armour E, Corry P, et al: Sublethal damage repair times for a late responding tissue relevant to brachytherapy (and external-beam radiotherapy): Implications for a new brachytherapy protocol. Int J Radiat Oncol Biol Phys 41: 135-138, 1998 (suppl 1)
6. Duchesne GM, Peters LJ: What is the α/β ratio for prostate cancer? Rationale for hypofractionated high-dose brachytherapy. Int J Radiat Oncol Biol Phys 44:747-748, 1999 (suppl 4)
7. Thames HDJ, Withers HR, Peters LJ, et al: Changes in early and late radiation responses with altered dose fractionation: Implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 8:219-226, 1982
8. Michalski JM, Purdy JA, Winter K, et al: Preliminary reports of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 46:391-402, 2000 (suppl 2)
9. Mclaughlin PW, Wygoda A, Sahudak W, et al: The effect of patient position and treatment techniques in conformal treatment of prostate cancer. Int J Radiat Oncol Biol Phys 45:407-413, 1999 (suppl 2)
10. Nag S, Gupta N: A simple method of obtaining equivalent doses for use in HDR brachytherapy. Int J Radiat Oncol Biol Phys 46:507-513, 2000 (suppl 2)
11. King C, DiPetrillo TA, Wazer DE: Optimal radiotherapy for prostate cancer predictions for conventional external beam IMRT, and brachytherapy from radiobiologic models. Int J Radiat Oncol Biol Phys 46:165-172, 2000 (suppl 1)
12. Wasserman T, Mackowiak JL, Brizel DM, et al: Effect on amifostine on patients assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys 48:1035-1039, 2000
13. Ethyol (amifostine for injection). Prescribing information, March 3, 2003. Gaithersburg, MD, MedImmune Oncology Inc.